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ABSTRACT
Gastric cancer remains the second most common GI cancer in the world, and is usually found in men, 
especially those over 50 years of age. Gastric cancer is a multifactorial disease resulting from the interaction 
between genetic and environmental factors at the stomach mucosa level. The diagnosis is made by endoscopic 
biopsy. The high frequency of late diagnosis or advanced stages accounts for the overall poor prognosis for this 
tumor. Surgery is the most frequently employed modality for both cure and palliation. However, most patients 
present with advanced disease that is incurable.
We reported a rare case of young male patient aged 24 years old with advanced gastric adenocarcinoma. 
The main clinical features were epigastric pain, vomiting, melena and weight loss. An abdominal mass was 
palpable on physical examination. Endoscopy showed a giant tumor mass causing gastric outlet obstruction, 
that appear edematous, there were hemorrhagic lesions. The histopathologic examination revealed poorly 
differentiated adenocarcinoma. Palliative resection could not be performed because the tumor tightly adhered 
to adjacent structures. Jejunostomy or nasojejunostomy tube were performed to allow enteral nutrition. Best 
supportive care is very important to improve the quality of life.
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ABSTRAK
Kanker lambung merupakan kanker saluran cerna kedua terbanyak di dunia, dan ditemukan pada pasien laki-
laki, yang berusia lebih dari 50 tahun. Penyebab kanker lambung akibat berbagai penyakit multifaktor seperti 
kelainan genetik, dan faktor mukosa lambung. Diagnosis kanker lambung dengan menggunakan pemeriksaan 
biopsi endoskopi. Banyaknya angka kejadian kanker lambung yang sudah stadium lanjut dan memiliki prognosis 
yang buruk. Pembedahaan merupakan tatalaksana paliatif pada pasien kanker lambung. Kebanyakan pasien 
dengan kanker lambung sudah memiliki stadium lanjut.
Kami melaporkan sebuah kasus yang sangat jarang ditemukan, seorang pasien laki-laki berusia 24 tahun 
dengan adenokarsinoma gaster stadium lanjut. Keluhan klinis berupa, nyeri epigastrium, muntah, melena, dan 
penurunan berat badan. Pemeriksaan fisik pada saat palpasi abdomen didapatkan adanya massa. Pemeriksaan 
histopatologi didapatkan adenokarsinoma gaster dengan diferensiasi buruk. Pada pasien ini tidak dilakukan 
reseksi paliatif karena tumor melekat kuat dan padat. Kami melakukan pemasangan yeyunostomi atau 
nasoyeyunostomi untuk pemberian nutrisi enteral. Perawatan suportif merupakan tatalaksana yang penting 
untuk meningkatkan kualitas hidup pasien.
Kata kunci: kanker lambung, pasien muda
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INTRODUCTION
Gastric cancer (GC) remains the second most 
common GI cancer in the world.1 GC is a heterogeneous, 
multi factorial disease. It endangers human physical 
and psychosocial wellbeing, causing a significant 
public health and economic burden both in the 
developed and developing countries.1 Globally, GC 
accounts for 989,600 new cases and 738,000 deaths 
annually.2 The case-fatality ratio of GC is higher than 
for common malignancies like colon, breast, and 
prostate cancers.1-2 Despite advances in diagnosis, 
the disease is usually detected after invasion of the 
muscularis propria, because most patients experience 
vague and nonspecific symptoms in the early stages 
and the classic triad of anemia, weight loss, and refusal 
of meat-based foods is seen only in advanced stages.2 
GC is distinguished into two forms, early GC and 
advanced GC. Early GC refers to invasion of the 
tumor limited to the mucosal and submucosal layers, 
whether or not regional lymph node metastases are 
present.3 The pathogenesis of GC is multi factorial, 
with both environmental and host factors playing a 
major role in its development. Among the risk factors 
for GC are consumption of smoked and salted food; 
nitrites, cigarette smoking; a lack of fiber in their diet, 
low socio- economic status; positive family history; 
A blood type; hereditary cancer syndrome (familial 
adenoma polyposis); Helicobacter pylori infection; 
and history of partial gastrectomy.4-6 The classic clinical 
symptoms and findings of GC are vague and non-specific, 
including epigastric pain, vomiting, nausea, bloating, 
early satiety, weight loss, abdominal mass, gastrointestinal 
bleeding, and sometimes dysphagia.7 Early GC may have 
no clinical symptoms. That is reason why most patients 
are diagnosed with GC at advanced stages of the disease. 
Gastroscopy is very crucial in making the diagnosis of 
GC.8 
Treatment of GC is mainly surgery. Other treatment 
modalities are chemotherapy and radiotherapy. There 
are two kinds of surgery: curative and non curative 
or palliation. Early GC can be cured by endoscopic 
therapy such as endoscopic mucosal resection (EMR), 
endoscopic submucosal dissection (ESD) or argon 
plasma coagulation (APC).5 In contrast, surgery for 
advanced GC is merely palliation. It has been reported 
that patients underwent palliative surgery had better 
prognoses than those who did not. Inoperable patients 
and those with metastatic disease have been subject 
to combination of chemotherapy and radiotherapy. 
The effectiveness of this therapeutic strategies is still 
controversial.3
CASE PRESENTATION
The patient, Mr A, 24 years, was admitted to the 
Army Gatot Soebroto Hospital with a chief complaint 
of nausea and vomiting since 2 months prior to 
admission. At first, he usually vomited 3-4 hours after 
meals. He also suffered recurrent epigastric pain and 
discomfort. He lost his appetite and lost a lot of weight 
in a short period of time. Eventually, he vomited more 
often. He could hardly eat any food because he vomited 
directly after swallowing it. He usually consumpt 
alcohol about two botols every weekend, and his 
daily diet was instant noodles everyday. He reported 
symptoms of gastrointestinal bleeding such as melena. 
The patient never had symptoms like this before. 
The patient was generally weak and cachectic. 
Physical examination revealed vital signs within normal 
range. The conjunctivae were pale, the sclera were 
jaundiced. Heart and lung examinations were within 
normal range. The liver were palpable. An abdominal 
mass was palpable, with a dimension of 8 x 6 x 4 cm. 
It was hard, immobile, and was non-tender. Superficial 
lymph nodes were not palpable. Laboratory examination 
results were as follows: Hemoglobin 5.8 g/dL; 
hematocryte 16%; leukocyte count 4580/mm; platelet 
count 111.000/mm; ureum level 21 mg/dL; creatinine 
level 2.4 mg/dL; blood glucose level 94 mg/dL; AST 
61 iu/mL; ALT 57 iu/ mL; total bilirubin 3.93 mg/dL; 
alkaline phosphatase 124 iu/mL; total protein 5,6 g/dL; 
albumin 4.1 mg/dL; globulin 2.0 mg/dL; cholinesterase 
2473 U/L; Gama GT 104 U/L; CEA 1.1; AFP 0.70 ng/
mL and CA19-9 4.5 U/mL ( normal < 37 U/mL) 
Endoscopy of the upper gastrointestinal tract revealed 
candidosis esofagus, with giant tumor mass causing 
gastric outlet obstruction, that appear edematous. There 
was no nodular ulcerative but there were hemorrhagic 
lesions. Some parts of the gaster were covered with fluid 
and indigested food. The tumor mass was suggested to 
be malignancy in the antrum (Figure 1). Nevertheless, 
the scope could still pass through, and we were examined 
histopathology biopsy to confirm the diagnosis and 
staging. Histopathological examination demonstrated 
gastric was displaying tumor cells nucleated round/
oval, pleomorphic, hyperchromatic, vesicular with 
nucleoli real partly, eosinophilic cytoplasm has a 
clear vacuoles partly. Mitosis is found (Figure 2). 
The histopathologic examination revealed poorly 
differentiated adenocarcinoma. 
The patient was given supportive care for nutrition, 
fluid and electrolyte balance. We immediately 
consulted to the Department of Surgery and the patient 
was prepared for surgical intervention. 
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DISCUSSION
GC is rare among young patient. It is usually found 
in older patients of over 55 years and is more common 
in men, particularly in East Asian countries.6-8 In 2012, 
there was an estimated 1 million new cases of GC, with 
half of the world total occurring in Eastern Asia.8 The 
highest mortality rates are observed in Eastern Asia, 
occurring at 24.0 per 100,000 men and 9.8 per 100,000 
women.8 However, prevention and screening programs 
for GC particularly at the national level have not yet 
been established in most countries. The exceptions are 
South Korea and Japan where GC screening programs 
have already been introduced. In Japan, GC screening 
using upper gastrointestinal series (radiographic 
screening) has been conducted as a national program 
since 1983, and it has been attributed to the decrease 
in GC mortality.8 This study had reported a worse 
outcome of GC in young patients compared to those 
who were older. 
Diagnosis is usually made after the disease reaches 
an advanced stage because early GC produces few 
Figure 1. Upper endoscopy shows tumor mass at the body 
of stomach, the mass is appear grow to the lumen of gaster, 
easy to bleed like cauliflower shaped mass, the size of tumor 
is about 8 x 6 x 4 cm
Figure 2. Histological tumor lesion was observed. A. Histological section was observed at 10 x. Showing gastric preparations 
with piston epithelial layer, which mostly erosive, still looks foveola gastric lamina propria accompanied by hard infiltration acute 
and chronic inflammatory cells. There intestinal metaplasia, with a mass of malignant tumor stroma of epithelial appear. It also 
seems that Bruner glands. B. Histological section was observed at 40 x. Observing malignant epithelial tumor masses composed 
granduler, partly infiltrative between stroma, with some hard infiltration acute and chronic inflammatory cells. C. Histological 
section was observed (around the tumor) at 40 x. Displaying tumor cells nucleated round/oval, pleomorphic, hyperchromatic, 
vesicular with nucleoli real partly, eosinophilic cytoplasm has a clear vacuoles partly. Mitosis is found. The histopathologic 
examination revealed poorly differentiated adenocarcinoma.
symptoms. Thus, early detection of the disease is very 
difficult. Therefore, most GC patients are diagnosed 
in advanced-stage disease with a poor prognosis.9 
Common symptoms are weight loss, epigastric pain, 
vomiting, nausea, anorexia, dysphagia, bloating, and 
regurgitation. It was often initially misdiagnosed as 
dyspepsia syndrome.6-8 The symptoms and signs of this 
patient such as nausea, vomiting and abdominal mass 
reflected the obstruction caused by advanced GC.5 The 
main treatment option is the gastrectomy combined 
with chemotherapy and radiation therapy protocols. 
The poor understanding of the pathogenic mechanisms 
of GC and etiological factors, and the lack of effective 
treatment are reflected in the late diagnosis and high 
mortality of this disease. GC is a multifactorial disease 
resulting from the interaction between genetic and 
environmental factors at the stomach mucosa level.9 
Cutsem EV et al stated that, a genetic basis causative 
mutations in CDH1 has been found in only around 
40% of families affected by hereditary diffuse GC. 
GC have been found in people with other hereditary 
cancer syndromes, such as gastric adenocarcinoma 
and proximal polyposis of the stomach syndrome, 
and in those with mutations in TP53 (Li-Fraumeni 
syndrome), APC (familial adenomatous polyposis), or 
STK11 (Peutz-Jeghers syndrome).10 Park J et al state 
that Several studies have been conducted to examine 
the association between GC, diabetes, and blood lipid 
profiles and instant noodle consumption.11 Instant 
noodle consumption is associated with a higher risk 
for GC compared with that of plain noodles (n = 105; 
OR = 4.76; p < 0.01).11 Gomez M et al concluded that 
GC is slightly more prevalent among young patients in 
their study than the prevalence that has been reported 
elsewhere in Columbia.12 the patients presented more 
advanced stages of cancer than did older patients, 
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and the majority of their cancers were diffuse types 
(90%) which resulted in a high mortality rate.12 Early 
performance of endoscopy is mandatory for young 
patients.12 In addition preventative measures such as 
genetic studies for CDH1 carriers to protect family 
members from this terrible disease should also be 
mandatory.11-12 Male carriers of a mutation in the CDH1 
gene have an 83% risk of developing GC while women 
who carry the mutation have a 67% diffuse GC risk.12 
Sun YQ et al concluded that, there are chromosomal 
maintenance (CRM1) and cyclin-dependent Kinase 
(CDK5) as co-expression was an independent 
prognostic factors for GC.13 Combined CRM1 and 
CDK5 expression had better prognostic power than 
their individual expression had.13 Chiurillo MA state 
that, The aberrant activation of the Wnt/β-catenin 
signaling pathway is involved in the development and 
progression of a significant proportion of GC cases. The 
role of key factors in Wnt/β-catenin signaling and their 
downstream effectors regulating processes involved 
in tumor initiation, tumor growth, metastasis and 
resistance to therapy.14 That constitutive Wnt signalling 
resulting from Helicobacter pylori infection and 
inactivation of Wnt inhibitors (mainly by inactivating 
mutations and promoter hypermethylation) play an 
important role in GC. Moreover, a number of recent 
studies confirmed CTNNB1 and Adematous Polyposis 
Coli (APC) as driver genes in GC. The identification 
of specific membrane, intracellular, and extracellular 
components of the Wnt pathway has revealed potential 
targets for GC therapy.14 High-throughput “omics” 
approaches will help in the search for Wnt pathway 
antagonist in the near future.14
Endoscopic screening for GC has shown promising 
results, and thus deserves further evaluation to 
reliably establish its effectiveness and optimal use.8 
Histopathological features of gastric tumor may aslo 
have prognostic value. In this patient, the histological 
lesion of GC found was displaying tumor cells 
nucleated round/oval, pleomorphic, hyperchromatic, 
vesicular with nucleoli real partly, eosinophilic 
cytoplasm has a clear vacuoles partly. Mitosis is found.
The treatment of GC depends on the stage of the 
disease. Surgery is still a major treatment modality 
for GC and could be curative or palliative. Most 
patients are first diagnosed at advanced, ‘inoperable’ 
stages.8 In this case, the tumor had progressively 
enlarged and caused obstruction of the gastric outlet. 
Resection of the tumor is still recommended for 
palliative treatment.8 Studies had reported that patients 
underwent palliative surgery had a better prognosis 
than those who did not. But the tumor was not removed 
because it was found to closely adhere to surrounding 
tissue and structures. Removal of the tumor would be 
very difficult and carried major risks of complications 
such as bleeding and perforation. Surgical intervention 
performed to this patient was jejunostomy, to allow 
enteral nutrition. A nasogastric tube was also inserted 
to drain the physiological secretions of the upper 
gastrointestinal tract.8
Metastasis is demonstrated to be an essential event 
in the prognosis of GC. Successful hematogenous 
metastasis cascade depends on intrinsic factors of 
the tumor cells and their subsequent communication 
with the surrounding microenvironment.14 During 
metastatic progression, tumor cells possess continuous 
interdependent strategies. First, tumor cells form 
a microenvironment, escape from primary site 
through surrounding extracellular matrix (ECM) 
and intravasate into the lumina of blood vessels.10 
Translocation system is then formed and circulating 
tumor cells (CTCs) survive in the circulation and arrest 
at the secondary organs. Subsequently, tumor cells 
survive with the microenvironment of distant tissues, 
thereby micrometastasis and metastatic colonization 
emerge.15
The prognosis of this patient was poor, Many 
GC patients are diagnosed at advanced stage with 
metastasis, and miss the possibility for curative 
resection. It has been documented that patients with 
advanced stage GC have a poor prognosis with a five-
year survival rate less than 15%.12-15
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